MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Reports, Plans, Studies, Proceedings, Analysis, Visualizations, Peer Reviewed Articles, Books, Publications, Rules & Policy Guidance
WIPO _ Which are the most innovative economies in 2026?
United States of America
Government: U.S. States & Territories
Government: States (U.S.)
Colorado
Industry: Colorado
Edgewise Therapeutics Inc. (NASDAQ: EWTX)*
Organization & Developments: Edgewise
Parents
Edgewise Therapeutics Inc. (NASDAQ: EWTX)*
Children
*The biopharma firm is developing treatments for various neuromuscular conditions including muscular dystrophies.
2021: According to a 2018 market research report by Grand View Research, the global market for Duchenne muscular dystrophy is expected to reach $4.1 billion by 2023. This represents a forecast CAGR (Compound Annual Growth Rate) of 41.3% from 2018 to 2023.
2021: The firm's lead candidate is EDG-5506, an oral small molecule inhibitor that is being tested as a treatment for Duchenne muscular dystrophy as well as Becker muscular dystrophy and Limb-girdle muscular dystrophy
2023: Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing_ seekingalpha.com
2024: Edgewise Therapeutics: Behind The Massive Rally_seekingalpha.com
2024: Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signa
2024: Edgewise Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones
2024: Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
2024: Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)
2024: Edgewise's stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos
2025: Edgewise Therapeutics: More Expensive Now, But Much More Derisked
Jumps
*Key People: Edgewise
Finance & Acquisitions: Edgewise